All In Biotech

Drug Trial Radar · NCT07285005

A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome

A Phase 3, Randomized, Parallel, Multicenter, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of KP 001 in Patients Aged ≥2 Years With Common Venous Malformations, Common Lymphatic Malformations, or KTS/CLOVES Syndrome

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

May 13, 2026

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Kaken PharmaceuticalIndustry
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, double-blind, randomized, placebo-controlled, parallel group, adaptive, multicenter study planned to be conducted at multiple sites in North America, Canada, Taiwan and South Korea. The purpose of this study is to measure the efficacy and safety of KP-001 compared with placebo in patients aged ≥2 years with common VM, common LM, or KTS/CLOVES syndrome. An independent data monitoring committee (DMC) will be established to determine whether to discontinue or continue the study. It will also determine the redesign of the number of cases based on the result of the interim analysis. The study will comprise the following: * Screening Period: Up to 42 days prior to the first dose of study intervention. * Treatment Period 1: This is a double-blind period in which KP-001 100 mg (or lower dose depending on their body weight) or placebo will be administered to patients once daily after breakfast until Week 24. * Treatment Period 2: After 24 weeks of double blind treatment, all patients will switch to the KP-001 open label extension and treated up to Week 52. * Follow-up Visit: This visit will occur 30 days after the last dose of study intervention, and assessments will be performed per the SoA. * Discontinuation Visit: Patients who discontinue study intervention will be requested to continue participating in the study and assessments will be performed per the SoA. If the patients request to withdraw from the study, all tests and evaluations when possible will be performed at Discontinuation visit.

Conditions

  • Venous Malformations
  • Lymphatic Malformations
  • Klippel-Trenaunay Syndrome
  • CLOVES Syndrome

Interventions

  • KP-001Drug

    Oral repeated dose 100mg or lower

  • PlaceboDrug

    Oral repeated dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The ratio of volume of target lesions based on MRITime frame: pre-does and at 24weeks post-dose

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Missouri - Columbia, School of Medicine

    Columbia, Missouri · Recruiting

  • UNC Health Care - North Carolina Children's Hospital

    Chapel Hill, North Carolina · Recruiting

  • MUSC Children's Health Primary Care

    Charleston, South Carolina · Recruiting

  • St. Jude Children's Research Hospital

    Memphis, Tennessee · Recruiting

  • Texas Children's Hospital

    Houston, Texas · Recruiting

  • West Virginia University

    Morgantown, West Virginia · Recruiting

  • Kyungpook National University Hospital - Pediatric

    Daegu, Daegu, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, Seoul, South Korea · Recruiting

  • National Taiwan University Hospital - HsinChu Branch

    Hsinchu, Hsinchu, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.